Taxus Cardium Pharmaceuticals Stock EBITDA

CRXMDelisted Stock  USD 0.0001  0.00  0.00%   
Taxus Cardium Pharmaceuticals fundamentals help investors to digest information that contributes to Taxus Cardium's financial success or failures. It also enables traders to predict the movement of Taxus Pink Sheet. The fundamental analysis module provides a way to measure Taxus Cardium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taxus Cardium pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Taxus Cardium Pharmaceuticals Company EBITDA Analysis

Taxus Cardium's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Taxus Cardium EBITDA

    
  (458.68 K)  
Most of Taxus Cardium's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Taxus Cardium Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (458,680). This is 100.05% lower than that of the Biotechnology sector and 100.46% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.01% higher than that of the company.

Taxus EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taxus Cardium's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taxus Cardium could also be used in its relative valuation, which is a method of valuing Taxus Cardium by comparing valuation metrics of similar companies.
Taxus Cardium is currently under evaluation in ebitda category among its peers.

Taxus Fundamentals

About Taxus Cardium Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Taxus Cardium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taxus Cardium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taxus Cardium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Taxus Pink Sheet

If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments